Program
abrocitinib
Also written as “PF-04965842”, “PF-04965842 200 mg” and “PF-04965842 100 mg”.
Its studies are mostly in Dermatitis, Atopic · Dermatitis · Eczema · Renal Insufficiency · Psoriasis, led by Pfizer.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 303 open or running | phase 3since Nov 17, 2017 | Apr 15, 2013 | May 2, 2027phase 3 · NCT06807268 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Apr 15, 2013.
- Aug 8, 20183 phase 1 studiesNCT03626415, NCT03634345, NCT03637790
- Sep 4, 20182 phase 1 studiesNCT03660241, NCT03662516
- Oct 24, 2018Phase 3 study in DermatitisNCT03720470 · 838 enrolled · United States, Australia, Bulgaria and more
- Nov 13, 2018Phase 1 study in HealthyNCT03742336 · 20 enrolled · Belgium
- Dec 9, 2018Named abrocitinibINNProposed as its International Nonproprietary Name in WHO's List 120 · before, PF-04965842
- Jan 4, 2019Phase 3 study in Dermatitis, AtopicNCT03796676 · 287 enrolled · United States, Australia, China and more
- Jan 4, 20192 phase 1 studiesNCT03796182, NCT03806101
- Mar 22, 2019Phase 2 study in Dermatitis, AtopicNCT03915496 · 46 enrolled · United States, Canada
- Sep 3, 2019Phase 1 study in HEALTHYNCT04099563 · 13 enrolled · China
- Mar 27, 2020Phase 3 study in Dermatitis, AtopicNCT04345367 · 727 enrolled · United States, Australia, Bulgaria and more
- May 21, 2021Phase 1 study in Dermatitis, AtopicNCT04903093 · 19 enrolled · United States
- Sep 24, 2021Phase 1 study in Healthy ParticipantsNCT05067439 · 26 enrolled · United States
- May 11, 2022Phase 3 study in Dermatitis, AtopicNCT05375929 · 200 enrolled · India
- Jan 29, 20252 phase 3 studiesNCT06807281, NCT06807268
- Sep 11, 2026Phase 3 study in Dermatitis, AtopicNCT07823595 · 90 planned
Ahead
- May 2, 2027Primary completion: phase 3 study in EczemaNCT06807268
- Apr 10, 2029Primary completion: phase 3 study in Dermatitis, AtopicNCT07823595
- Feb 22, 2032Primary completion: phase 3 study in Dermatitis, AtopicNCT06807281
TargetBeta
“Tyrosine-protein kinase JAK1 inhibitor”ChEMBL 37, by rule
Other programs on JAK1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| baricitinibrule | Eli Lilly | phase 4 | 59 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| jaktinibrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 31 |
| ivarmacitinibrule | Jiangsu HengRui Medicine | phase 3 | 25 |
| brepocitinibrule | Pfizer | phase 3 | 25 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| momelotinibrule | GlaxoSmithKline | phase 3 | 17 |
| golidocitinibrule | Dizal Pharmaceuticals | phase 3 | 10 |
Studies
All 30 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07823595Dermatitis, Atopic | 3 | Not yet recruiting | Apr 10, 2029 | 90 |
| NCT06807281Dermatitis, Atopic · United States, China, Hungary and more | 3 | Recruiting | Feb 22, 2032 | 450 |
| NCT06807268Eczema · United States, China, Germany and more | 3 | Active, not recruiting | May 2, 2027 | 151 |
| NCT05375929Dermatitis, Atopic · India | 3 | Completed | Jun 9, 2023 | 200 |
| NCT05067439Healthy Participants · United States | 1 | Completed | Feb 26, 2022 | 26 |
| NCT04903093Dermatitis, Atopic · United States | 1 | Completed | Oct 26, 2021 | 19 |
| NCT04345367Dermatitis, Atopic · United States, Australia, Bulgaria and more | 3 | Completed | Jul 13, 2021 | 727 |
| NCT04099563HEALTHY · China | 1 | Completed | Nov 9, 2019 | 13 |
| NCT03915496Dermatitis, Atopic · United States, Canada | 2 | Completed | Nov 16, 2021 | 46 |
| NCT03806101Healthy · Belgium | 1 | Completed | Mar 15, 2019 | 12 |
| NCT03796676Dermatitis, Atopic · United States, Australia, China and more | 3 | Completed | Apr 8, 2020 | 287 |
| NCT03796182Dermatitis, Atopic · Belgium | 1 | Completed | Feb 13, 2019 | 12 |
| NCT03742336Healthy · Belgium | 1 | Completed | Feb 18, 2019 | 20 |
| NCT03720470Dermatitis · United States, Australia, Bulgaria and more | 3 | Completed | Dec 27, 2019 | 838 |
| NCT03662516Healthy Females · United States | 1 | Completed | Jan 19, 2019 | 17 |
| NCT03660241Renal Insufficiency · United States, Belgium | 1 | Completed | Nov 5, 2019 | 23 |
| NCT03637790Healthy · Belgium | 1 | Completed | Dec 14, 2018 | 12 |
| NCT03634345Dermatitis, Atopic · Belgium | 1 | Completed | Dec 13, 2018 | 24 |
| NCT03626415Hepatic Impairment · United States | 1 | Completed | Apr 30, 2019 | 24 |
| NCT03647670Phase 1 · Belgium | 1 | Completed | Oct 16, 2018 | 25 |
| NCT03575871Dermatitis, Atopic · United States, Australia, Bulgaria and more | 3 | Completed | Aug 13, 2019 | 391 |
| NCT03627767Dermatitis · United States, Argentina, Belgium and more | 3 | Completed | Sep 2, 2020 | 1,235 |
| NCT03386279Healthy Volunteers · Belgium | 1 | Completed | Oct 1, 2018 | 36 |
| NCT03422822Dermatitis, Atopic · United States, Argentina, Australia and more | 3 | Completed | Dec 22, 2025 | 3,166 |
| NCT03349060Dermatitis, Atopic · United States, Australia, Canada and more | 3 | Completed | Mar 26, 2019 | 387 |
| NCT03250039Healthy · Netherlands | 1 | Completed | Sep 15, 2017 | 6 |
| NCT02780167Dermatitis, Atopic · United States, Australia, Canada and more | 2 | Completed | Mar 2017 | 269 |
| NCT02201524Plaque, Amyloid · United States, Canada | 2 | Terminated | Sep 2015 | 59 |
| NCT02163161Fasting · Belgium | 1 | Completed | Aug 2014 | 12 |
| NCT01835197Healthy · United States | 1 | Completed | Jun 2014 | 79 |
How it is read
Names in the registry
- “PF-04965842”, 26 entries
- “PF-04965842 200 mg”, 5 entries
- “PF-04965842 100 mg”, 5 entries
- “Abrocitinib”, 4 entries
- “Abrocitinib 200 mg”, 4 entries
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 13 studies
- Dermatitis, 2 studies
- Eczema, 1 study
- Renal Insufficiency, 1 study
- Psoriasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.